Cargando…
Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia
INTRODUCTION: In healthy carriers of the T allele of the transcription factor 7-like 2 (TCF7L2), fasting plasma glucagon concentrations are lower compared with those with the C allele. We hypothesised that presence of the T allele is associated with a diminished glucagon response during hypoglycaemi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097143/ https://www.ncbi.nlm.nih.gov/pubmed/27758844 http://dx.doi.org/10.1530/EC-16-0050 |
_version_ | 1782465563060076544 |
---|---|
author | Kristensen, Peter L Pedersen-Bjergaard, Ulrik Due-Andersen, Rikke Høi-Hansen, Thomas Grimmeshave, Lise Lyssenko, Valeriya Groop, Leif Holst, Jens J Vaag, Allan A Thorsteinsson, Birger |
author_facet | Kristensen, Peter L Pedersen-Bjergaard, Ulrik Due-Andersen, Rikke Høi-Hansen, Thomas Grimmeshave, Lise Lyssenko, Valeriya Groop, Leif Holst, Jens J Vaag, Allan A Thorsteinsson, Birger |
author_sort | Kristensen, Peter L |
collection | PubMed |
description | INTRODUCTION: In healthy carriers of the T allele of the transcription factor 7-like 2 (TCF7L2), fasting plasma glucagon concentrations are lower compared with those with the C allele. We hypothesised that presence of the T allele is associated with a diminished glucagon response during hypoglycaemia and a higher frequency of severe hypoglycaemia (SH) in type 1 diabetes (T1DM). MATERIAL AND METHODS: This is a post hoc study of an earlier prospective observational study of SH and four mechanistic studies of physiological responses to hypoglycaemia. 269 patients with T1DM were followed in a one-year observational study. A log-linear negative binomial model was applied with events of SH as dependent variable and TCF7L2 alleles as explanatory variable. In four experimental studies including 65 people, TCF7L2 genotyping was done and plasma glucagon concentration during experimental hypoglycaemia was determined. RESULTS: Incidences of SH were TT 0.54, TC 0.98 and CC 1.01 episodes per patient-year with no significant difference between groups. During experimental hypoglycaemia, the TCF7L2 polymorphism did not influence glucagon secretion. DISCUSSION: Patients with T1DM carrying the T allele of the TCF7L2 polymorphism do not exhibit diminished glucagon response during hypoglycaemia and are not at increased risk of severe hypoglycaemia compared with carriers of the C allele. |
format | Online Article Text |
id | pubmed-5097143 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-50971432016-11-14 Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia Kristensen, Peter L Pedersen-Bjergaard, Ulrik Due-Andersen, Rikke Høi-Hansen, Thomas Grimmeshave, Lise Lyssenko, Valeriya Groop, Leif Holst, Jens J Vaag, Allan A Thorsteinsson, Birger Endocr Connect Research INTRODUCTION: In healthy carriers of the T allele of the transcription factor 7-like 2 (TCF7L2), fasting plasma glucagon concentrations are lower compared with those with the C allele. We hypothesised that presence of the T allele is associated with a diminished glucagon response during hypoglycaemia and a higher frequency of severe hypoglycaemia (SH) in type 1 diabetes (T1DM). MATERIAL AND METHODS: This is a post hoc study of an earlier prospective observational study of SH and four mechanistic studies of physiological responses to hypoglycaemia. 269 patients with T1DM were followed in a one-year observational study. A log-linear negative binomial model was applied with events of SH as dependent variable and TCF7L2 alleles as explanatory variable. In four experimental studies including 65 people, TCF7L2 genotyping was done and plasma glucagon concentration during experimental hypoglycaemia was determined. RESULTS: Incidences of SH were TT 0.54, TC 0.98 and CC 1.01 episodes per patient-year with no significant difference between groups. During experimental hypoglycaemia, the TCF7L2 polymorphism did not influence glucagon secretion. DISCUSSION: Patients with T1DM carrying the T allele of the TCF7L2 polymorphism do not exhibit diminished glucagon response during hypoglycaemia and are not at increased risk of severe hypoglycaemia compared with carriers of the C allele. Bioscientifica Ltd 2016-11-03 /pmc/articles/PMC5097143/ /pubmed/27758844 http://dx.doi.org/10.1530/EC-16-0050 Text en © 2016 The authors http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Research Kristensen, Peter L Pedersen-Bjergaard, Ulrik Due-Andersen, Rikke Høi-Hansen, Thomas Grimmeshave, Lise Lyssenko, Valeriya Groop, Leif Holst, Jens J Vaag, Allan A Thorsteinsson, Birger Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia |
title | Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia |
title_full | Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia |
title_fullStr | Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia |
title_full_unstemmed | Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia |
title_short | Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia |
title_sort | impact of the tcf7l2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097143/ https://www.ncbi.nlm.nih.gov/pubmed/27758844 http://dx.doi.org/10.1530/EC-16-0050 |
work_keys_str_mv | AT kristensenpeterl impactofthetcf7l2genotypeonriskofhypoglycaemiaandglucagonsecretionduringhypoglycaemia AT pedersenbjergaardulrik impactofthetcf7l2genotypeonriskofhypoglycaemiaandglucagonsecretionduringhypoglycaemia AT dueandersenrikke impactofthetcf7l2genotypeonriskofhypoglycaemiaandglucagonsecretionduringhypoglycaemia AT høihansenthomas impactofthetcf7l2genotypeonriskofhypoglycaemiaandglucagonsecretionduringhypoglycaemia AT grimmeshavelise impactofthetcf7l2genotypeonriskofhypoglycaemiaandglucagonsecretionduringhypoglycaemia AT lyssenkovaleriya impactofthetcf7l2genotypeonriskofhypoglycaemiaandglucagonsecretionduringhypoglycaemia AT groopleif impactofthetcf7l2genotypeonriskofhypoglycaemiaandglucagonsecretionduringhypoglycaemia AT holstjensj impactofthetcf7l2genotypeonriskofhypoglycaemiaandglucagonsecretionduringhypoglycaemia AT vaagallana impactofthetcf7l2genotypeonriskofhypoglycaemiaandglucagonsecretionduringhypoglycaemia AT thorsteinssonbirger impactofthetcf7l2genotypeonriskofhypoglycaemiaandglucagonsecretionduringhypoglycaemia |